Guanfacine extended release: A novel treatment for attention-deficit/ hyperactivity disorder in children and adolescents

Clinical Therapeutics

Volumn 35, Issue 11, 2013, Pages 1778-1793

  Faraone, Stephen V ^a   McBurnett, Keith ^b   Sallee, Floyd R ^c   Steeber, Jennifer ^d   López, Frank A ^e  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d Ogilvy CommonHealth Insights and Analytics   (United States)

^e Children's Developmental Center   (United States)

Author keywords

alpha adrenergic receptor agonists; attention deficit hyperactivity disorder; efficacy; guanfacine extended release; nonstimulant; safety

Indexed keywords

GUANFACINE; KETOCONAZOLE;

ABDOMINAL PAIN; ADOLESCENT DISEASE; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR SYSTEM; CHILDHOOD DISEASE; CONSTIPATION; COUGHING; DECREASED APPETITE; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; HEADACHE; HEART RATE; HUMAN; HYPERSOMNIA; HYPOTENSION; IRRITABILITY; LETHARGY; MONOTHERAPY; NAUSEA; PHARYNGITIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ALPHA ADRENERGIC RECEPTOR AGONISTS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; EFFICACY; GUANFACINE EXTENDED RELEASE; NONSTIMULANT; SAFETY;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DATABASES, BIBLIOGRAPHIC; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GUANFACINE; HUMANS;

EID: 84888013633     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.005     Document Type: Article

References (78)

1. S.V. Faraone, J. Sergeant, C. Gillberg, and J. Biederman The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2 2003 104 113
2. B. Bloom, R.A. Cohen, and G. Freeman Summary health statistics for US children: National Health Interview Survey, 2007 Vital Health Stat 10 2009 1 80
3. B. Hoza Peer functioning in children with ADHD Ambul Pediatr 7 Suppl 1 2007 101 106
4. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, Fourth Edition. Text Revision. Washington, DC: American Psychiatric Association; 2000:85-93.
5. M.I. Reiff, and M.T. Stein Attention-deficit/hyperactivity disorder evaluation and diagnosis. A practical approach in office practice Pediatr Clin North Am 50 2003 1019 1048
6. J. Biederman, M.C. Monuteaux, and A.E. Doyle Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children J Consult Clin Psychol 72 2004 757 766
7. R.W. Greene, J. Biederman, and S.V. Faraone Adolescent outcome of boys with attention-deficit/hyperactivity disorder and social disability: results from a 4-year longitudinal follow-up study J Consult Clin Psychol 65 1997 758 767
8. J. Biederman, C.R. Petty, and R. Fried Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD Acta Psychiatr Scand 116 2007 129 136
9. R.A. Barkley, D.C. Guevremont, and A.D. Anastopoulos Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey Pediatrics 92 1993 212 218
10. S. Mannuzza, R.G. Klein, and J.L. Moulton III Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records Psychiatry Res 160 2008 237 246
11. S.V. Faraone, J. Biederman, and E. Mick The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies Psychol Med 36 2006 159 165
12. E. Mick, S.V. Faraone, and T. Spencer Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form in adults with ADHD J Atten Disord 11 2008 504 509
13. J. Biederman, S.V. Faraone, and T.J. Spencer Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community J Clin Psychiatry 67 2006 524 540
14. J. Biederman, C. Petty, and R. Fried Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder Am J Psychiatry 163 2006 1730 1738
15. J. Biederman, C.R. Petty, and A.E. Doyle Stability of executive function deficits in girls with ADHD: a prospective longitudinal followup study into adolescence Dev Neuropsychol 33 2008 44 61
16. E.G. Willcutt, A.E. Doyle, and J.T. Nigg Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review Biol Psychiatry 57 2005 1336 1346
17. R.M. Roth, and A.J. Saykin Executive dysfunction in attention-deficit/ hyperactivity disorder: cognitive and neuroimaging findings Psychiatr Clin North Am 27 2004 83 96
18. A.F.T. Arnsten, and B.M. Li Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions Biol Psychiatry 57 2005 1377 1384
19. S.R. Pliszka, M.L. Crismon, and C.W. Hughes The Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 45 2006 642 657
20. M. Olfson New options in the pharmacological management of attention-deficit/hyperactivity disorder Am J Manag Care 10 Suppl 2004 S117 S124
21. American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 46 2007 894 921
22. J. Biederman, and S.V. Faraone Attention-deficit hyperactivity disorder Lancet 366 2005 237 248
23. L.L. Greenhill, S. Pliszka, and M.K. Dulcan Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults J Am Acad Child Adolesc Psychiatry 41 Suppl 2 2002 26S 49S
24. S.V. Faraone, and J. Buitelaar Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis Eur Child Adolesc Psychiatry 19 2009 353 364
25. L. Scahill, P.B. Chappell, and Y.S. Kim A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder Am J Psychiatry 158 2001 1067 1074
26. J. Biederman, R.D. Melmed, and A. Patel for the SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder Pediatrics 121 2008 e73 e84
27. J. Elia, P.J. Ambrosini, and J.L. Rapoport Treatment of attention-deficit-hyperactivity disorder N Engl J Med 340 1999 780 788
28. J.G. Wood, J.L. Crager, C.M. Delap, and K.D. Heiskell Beyond methylphenidate: nonstimulant medications for youth with ADHD J Atten Disord 11 2007 341 350
29. X.R. Adderall [package insert] 2011 Shire US Inc Wayne, Pa
30. L.A. Ritalin [package insert] 2010 Novartis Pharmaceuticals Corporation East Hanover, NJ
31. T.E. Wilens, S.V. Faraone, J. Biederman, and S. Gunawardene Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature Pediatrics 111 2003 179 185
32. J. Biederman, M.C. Monuteaux, and T. Spencer Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study Pediatrics 124 2009 71 78
33. S.V. Faraone, and T.E. Wilens Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion J Clin Psychiatry 68 Suppl 11 2007 15 22
34. S. Dosreis, J.M. Zito, and D.J. Safer Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder J Dev Behav Pediatr 24 2003 155 162
35. S.V. Faraone, J. Biederman, C.P. Morley, and T.J. Spencer Effect of stimulants on height and weight: a review of the literature J Am Acad Child Adolesc Psychiatry 47 2008 994 1009
36. Strattera [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2011.
37. J.H. Newcorn, C.J. Kratochvil, and A.J. Allen Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response Am J Psychiatry 165 2008 721 730
38. S.V. Faraone Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder Expert Opin Pharmacother 9 2008 1565 1574
39. M.A. Stein Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments Am J Manag Care 10 Suppl 2004 S89 S98
40. P.B. Chappell, M.A. Riddle, and L. Scahill Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience J Am Acad Child Adolesc Psychiatry 34 1995 1140 1146
41. R.D. Hunt, A.F.T. Arnsten, and M.D. Asbell An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder J Am Acad Child Adolesc Psychiatry 34 1995 50 54
42. Shojaei AH, Chang RK, Pennick M. Guanfacine extended release tablets as treatment for attention-deficit/hyperactivity disorder: formulation characteristics. Poster presented at: US Psychiatric & Mental Health Congress; November 16-19, 2006; New Orleans, La.
43. S.W. Boellner, M. Pennick, and K. Fiske Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder Pharmacotherapy 27 2007 1253 1262
44. D. Swearingen, M. Pennick, and A. Shojaei A Phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults Clin Ther 29 2007 617 625
45. D.F. Connor, and R.J. Steingard New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential CNS Drugs 18 2004 1011 1030
46. Intuniv [package insert]. Wayne, Pa: Shire Pharmaceuticals Inc; 2011.
47. J. Biederman, R.D. Melmed, and A. Patel Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD CNS Spectr 13 2008 1047 1055
48. D.F. Connor, R.L. Findling, and S.H. Kollins Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial CNS Drugs 24 2010 755 768
49. S.V. Faraone, and S.J. Glatt Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD J Atten Disord 13 2009 532 538
50. J.C. Kisicki, K. Fiske, and A. Lyne Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years Clin Ther 29 2007 1967 1979
51. Turnbow JM, Kollins SH, Lopez FA, et al. Response to guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Poster presented at: Society of Biological Psychiatry 65th Annual Meeting; May 20-22, 2010; New Orleans, La.
52. F. Sallee, J. McGough, and T. Wigal for the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial J Am Acad Child Adolesc Psychiatry 48 2009 155 165
53. F.R. Sallee, A. Lyne, T. Wigal, and J.J. McGough Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder J Child Adolesc Psychopharmacol 19 2009 215 226
54. T.J. Spencer, M. Greenbaum, L.D. Ginsberg, and W.R. Murphy Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder J Child Adolesc Psychopharmacol 19 2009 501 510
55. T.E. Wilens, O. Bukstein, and M. Brams A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder J Am Acad Child Adolesc Psychiatry 51 2012 74 85
56. Rubin J, Lopez FA, Youcha S. Impact of guanfacine extended release on cognitive problems and inattention. Poster presented at: 2010 Annual Meeting of the Society for Developmental and Behavioral Pediatrics Annual Meeting; September 11-14, 2010; Boston, Mass.
57. Lopez FA, White C, Rubin J. Effects of guanfacine extended release on parent-reported behaviors in a randomized double-blind study of subjects with attention-deficit/hyperactivity disorder. Poster presented at: American Professional Society of ADHD and Related Disorders; November 5-6, 2010; Washington, DC.
58. C. Drake, C. Nickel, and E. Burduvali The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children Sleep 26 2003 455 458
59. Sallee F, Wigal T, Youcha S, et al. Impact of long-term guanfacine extended release treatment on quality of life. Poster presented at: 164th Annual Meeting of the American Psychiatric Association; May 14-18, 2011; Honolulu, HI.
60. Melmed R, Rubin J, Youcha S. Quality of life changes associated with long-term guanfacine extended release treatment. Poster presented at: 2010 Annual Meeting of the Society for Developmental and Behavioral Pediatrics; September 11-14, 2010; Boston, Mass.
61. Kollins SH, Wigal T, Vince B, et al. Cognitive and sedative effects of guanfacine extended release in children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder. Poster presented at: Society of Biological Psychiatry 63rd Annual Scientific Meeting; May 1-3, 2008; Washington, DC.
62. J.M. Perrin, R.A. Friedman, and T.K. Knilans Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder Pediatrics 122 2008 451 453
63. R. Mosqueda-Garcia Guanfacine: a second generation alpha 2-adrenergic blocker Am J Med Sci 299 1990 73 76
64. D.A. Lewis, and A. Dhala Syncope in the pediatric patient. The cardiologist's perspective Pediatr Clin North Am 46 1999 205 219
65. K.S. Ganzeboom, N. Colman, and J.B. Reitsma Prevalence and triggers of syncope in medical students Am J Cardiol 91 2003 1006 1008
66. D.J. Driscoll, S.J. Jacobsen, C.J. Porter, and P.C. Wollan Syncope in children and adolescents J Am Coll Cardiol 29 1997 1039 1045
67. A. King, P. Harris, J. Fritzell, and R. Kurlan Syncope in children with Tourette's syndrome treated with guanfacine Mov Disord 21 2006 419 420
68. A.F.T. Arnsten, J.X. Cai, and P.S. Goldman-Rakic The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes J Neurosci 8 1988 4287 4298
69. 2A-selective compound Eur J Pharmacol 202 1991 235 243
70. J.S. Franowicz, L.E. Kessler, and C.M. Borja Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine J Neurosci 22 2002 8771 8777
71. E.M. Sorkin, and R.C. Heel Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension Drugs 31 1986 301 336
72. A.F. Arnsten, L. Scahill, and R.L. Findling Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data J Child Adolesc Psychopharmacol 17 2007 393 406
73. K. Gyires, Z.S. Zadori, T. Torok, and P. Matyus alpha(2)-Adrenoceptor subtypes-mediated physiological, pharmacological actions Neurochem Int 55 2009 447 453
74. A.F.T. Arnsten, J.C. Steere, and R.D. Hunt The contribution of alpha 2-noradrenergic mechanisms to prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder Arch Gen Psychiatry 53 1996 448 455
75. M. Wang, B.P. Ramos, and C.D. Paspalas Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex Cell 129 2007 397 410
76. Arnsten AFT. Stimulants: therapeutic actions in ADHD Neuropsychopharmacology 31 2006 2376 2383
77. A.F. Arnsten, and A.G. Dudley Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder Behav Brain Funct 1 2005 2
78. S.V. Faraone, and S.J. Glatt A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes J Clin Psychiatry 71 2010 754 763